Dignity Sciences Acquires Patent Application

Share Article

Enables topical formulations of Dignity Sciences’ lead compound and follow-on compounds.

News Image

Dignity Sciences Ltd today announced that it has signed an assignment agreement with Equateq to acquire patent application PCT/GB2010/000844. The terms of the agreement were undisclosed. The patent application enables the prosecution of claims that would cover topical formulations of Dignity Sciences’ lead compound, DS107, and the company’s highly promising second generation compounds.

Jonathan D. Rowe, Ph.D., Head of Intellectual Property and Portfolio Strategy for Dignity Sciences, stated, "The development and acquisition of intellectual property is a cornerstone of Dignity Sciences’ product development model. This is an ideal agreement, allowing each company to focus on its strengths. Dignity Sciences has the expertise to bring these compounds to market, and Equateq has the know-how and capability to best manufacture the active ingredients."

Adam Kelliher, Equateq CEO and founder, said: “Dignity understands the vast potential of these novel compounds, which hold great promise for providing effective treatment for chronic skin conditions, with no side effects. We look forward to supporting their plans to prove robust clinical efficacy, and ultimately, bringing these APIs to market.”

About Equateq
Equateq is a privately-owned lipid production company based in the Western Isles of Scotland, where its facility has been concentrating lipids for nearly 30 years. Equateq is fully cGMP compliant, as certified by the UK's health authority, the MHRA, and for manufacturing lipid APIs, uses its Maxomega™ technology. This concentration method is based on advanced HPLC separation, and allows Equateq to deliver specific lipid APIs at up to 99% purity at commercial scale.

About DS107
DS107 is a topical formulation of a semi-synthetic omega-6 fatty acid. DS107 is currently being studied for use in treating acne and atopic dermatitis.

About Dignity Sciences
Dignity Sciences, a privately held biopharmaceutical company, was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life for people with diseases for which current therapies are unsatisfactory. Dignity Sciences is led by recognized experts in developing omega-6 and omega-3 fatty acids, including their bioactive derivatives, for the treatment of human disease.

Contact:
Dignity Sciences Ltd
Jonathan Rowe PhD
Investor(dot)relations(at)dignitysciences(dot)com
+353 1 2933590 (IE)

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jonathan Rowe
investor.relations@dignitysciences.com
+353 1 2933 590
Email >
Visit website